ConductScience.org, home

Paper27322425

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

Löffler H and 10 others. Oncotarget, 2016. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Papers, record 27322425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27322425

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
PubMed
Journal
Oncotarget
PubMed
Year
2016
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
1.3
iCite
Revised in PubMed
2022-04-19
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Löffler HHarald
2Pfarr NNicole
3Kriegsmann MMark
4Endris VVolker
5Hielscher TThomas
6Lohneis PPhilipp
7Folprecht GGunnar
8Stenzinger AAlbrecht
9Dietel MManfred
10Weichert WWilko
11Krämer AAlwin

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplasms, Unknown PrimaryMajor topic
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p18
DNA Mutational Analysis
Female
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Proto-Oncogene Proteins p21(ras)
Tumor Suppressor Protein p53

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111902578Assessing TP53 status in human tumours to evaluate clinical outcome.Nat Rev Cancer2001https://conductscience.org/library/papers/11902578PubMed
226376137Acute Myeloid Leukemia.N Engl J Med2015https://conductscience.org/library/papers/26376137PubMed
325323927Drugging the undruggable RAS: Mission possible?Nat Rev Drug Discov2014https://conductscience.org/library/papers/25323927PubMed
420697090TP53 mutation and survival in chronic lymphocytic leukemia.J Clin Oncol2010https://conductscience.org/library/papers/20697090PubMed
520551152The path to personalized medicine.N Engl J Med2010https://conductscience.org/library/papers/20551152PubMed
617055429The regulation of INK4/ARF in cancer and aging.Cell2006https://conductscience.org/library/papers/17055429PubMed
78632491The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.J Natl Cancer Inst1996https://conductscience.org/library/papers/8632491PubMed
823973117Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.J Mol Diagn2013https://conductscience.org/library/papers/23973117PubMed
99927204Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.Oncogene1999https://conductscience.org/library/papers/9927204PubMed
103738291Censoring distributions as a measure of follow-up in survival analysis.Stat Med1986https://conductscience.org/library/papers/3738291PubMed
1119692681Personalized medicine and inhibition of EGFR signaling in lung cancer.N Engl J Med2009https://conductscience.org/library/papers/19692681PubMed
1226182302Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.JAMA Oncol2015https://conductscience.org/library/papers/26182302PubMed
1312562643The unknown biology of the unknown primary tumour: a literature review.Ann Oncol2003https://conductscience.org/library/papers/12562643PubMed
1425409386Carcinoma of unknown primary site.N Engl J Med2014https://conductscience.org/library/papers/25409386PubMed
1523480555Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.Eur J Clin Invest2013https://conductscience.org/library/papers/23480555PubMed
1626404825Somatic mutation in cancer and normal cells.Science2015https://conductscience.org/library/papers/26404825PubMed
177550353Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.Nat Genet1995https://conductscience.org/library/papers/7550353PubMed
1811595686Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.Clin Cancer Res2001https://conductscience.org/library/papers/11595686PubMed
1919623297Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome.Dtsch Arztebl Int2008https://conductscience.org/library/papers/19623297PubMed
2021388974BRAFV600E: implications for carcinogenesis and molecular therapy.Mol Cancer Ther2011https://conductscience.org/library/papers/21388974PubMed

See all 36 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42681672Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomark Res2026https://conductscience.org/library/papers/42681672PubMed
42477427A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP).Br J Cancer2026https://conductscience.org/library/papers/42477427PubMed
41806238SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025).Clin Transl Oncol2026https://conductscience.org/library/papers/41806238PubMed
41122443Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population.J Res Med Sci2025https://conductscience.org/library/papers/41122443PubMed
39292320A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin.Int J Clin Oncol2024https://conductscience.org/library/papers/39292320PubMed
38404120Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.Cancer Med2024https://conductscience.org/library/papers/38404120PubMed
37875494Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.Nat Commun2023https://conductscience.org/library/papers/37875494PubMed
37519592Adenocarcinoma of an Unknown Primary Site: Presentation, Diagnosis, and Management.Cureus2023https://conductscience.org/library/papers/37519592PubMed
37359927Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site-a Review.Indian J Surg Oncol2023https://conductscience.org/library/papers/37359927PubMed
36722641Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary.EMBO Mol Med2023https://conductscience.org/library/papers/36722641PubMed
36287571A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.J Pathol2023https://conductscience.org/library/papers/36287571PubMed
35918329Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Nat Commun2022https://conductscience.org/library/papers/35918329PubMed
35320504SEOM-GECOD clinical guideline for unknown primary cancer (2021).Clin Transl Oncol2022https://conductscience.org/library/papers/35320504PubMed
34302033Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).Sci Rep2021https://conductscience.org/library/papers/34302033PubMed
33516660Cancer of Unknown Primary in the Molecular Era.Trends Cancer2021https://conductscience.org/library/papers/33516660PubMed
33504059Cancer of Unknown Primary: Challenges and Progress in Clinical Management.Cancers (Basel)2021https://conductscience.org/library/papers/33504059PubMed
32511869Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report.EMBO Mol Med2020https://conductscience.org/library/papers/32511869PubMed
32457826The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.Front Oncol2020https://conductscience.org/library/papers/32457826PubMed
32350398Progress in refining the clinical management of cancer of unknown primary in the molecular era.Nat Rev Clin Oncol2020https://conductscience.org/library/papers/32350398PubMed
32010631"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?Front Oncol2019https://conductscience.org/library/papers/32010631PubMed

See all 26 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27322425

GET https://conductscience.org/api/papers/v1/27322425/references?page=2